



Immunosuppression in Ovarian Cancer and the Path to Successful Immunotherapy

Guest Editor:

Prof. Dr. An Coosemans

Department of Oncology,
Laboratory of Tumor
Immunology and
Immunotherapy, KU Leuven,
O&N1 box 603, Herestraat 49,
3000 Leuven, Belgium

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Dear Colleagues,

Ovarian cancer has the fifth highest mortality rate among women diagnosed with cancer in Europe. Ovarian cancer is a silent killer, metastasizing throughout the abdomen before causing any symptoms.

The immune system is now known to play a pivotal role in the onset and development of cancer. The adaptive and innate immune responses are mobilized to eliminate neoplastic cells as they emerge. In some cases, elimination is not entirely successful and an equilibrium phase is established, whereby neoplastic cells enter a dormant state, side by side with the immune system.

Understanding and dealing with the specific immune biology of ovarian cancer is a mandatory key to successful immunotherapy. Therefore, we believe it is necessary to group all relevant information on this topic to increase the power of immunotherapeutic strategies in ovarian cancer.

Prof. Dr. An Coosemans
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI